Evidence map›Paper›PMID 27821447›Full record

ArticleAntimicrobial agents and chemotherapy2017

Synthetic Organotellurium Compounds Sensitize Drug-Resistant Candida albicans Clinical Isolates to Fluconazole.

L F Reis de Sá, F T Toledo, A C Gonçalves, B A Sousa, A A Dos Santos, P F Brasil, V A Duarte da Silva, A C Tessis, J A Ramos, M A Carvalho and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Digoxin Derivatives Sensitize aJournal of fungi (Basel, Switzerland) · 2022
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

L F Reis de SáLaboratório de Bioquímica Microbiana, Departamento de Microbiologia Geral, IMPG/CCS, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
F T ToledoLaboratório de Organocatálise e Síntese Orgânica, Instituto de Química, Departamento de Química Fundamental, Universidade de São Paulo, São Paulo, Brazil.
A C GonçalvesLaboratório de Organocatálise e Síntese Orgânica, Instituto de Química, Departamento de Química Fundamental, Universidade de São Paulo, São Paulo, Brazil.
B A SousaLaboratório de Organocatálise e Síntese Orgânica, Instituto de Química, Departamento de Química Fundamental, Universidade de São Paulo, São Paulo, Brazil.
A A Dos SantosLaboratório de Organocatálise e Síntese Orgânica, Instituto de Química, Departamento de Química Fundamental, Universidade de São Paulo, São Paulo, Brazil.
P F BrasilLaboratório de Bioquímica Microbiana, Departamento de Microbiologia Geral, IMPG/CCS, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
V A Duarte da SilvaLaboratório de Bioquímica Microbiana, Departamento de Microbiologia Geral, IMPG/CCS, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
A C TessisLaboratório de Bioquímica Microbiana, Departamento de Microbiologia Geral, IMPG/CCS, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
J A RamosInstituto Federal de Educação, Ciência e Tecnologia, Rio de Janeiro, Brazil.
M A CarvalhoInstituto Federal de Educação, Ciência e Tecnologia, Rio de Janeiro, Brazil.
E LampingDepartment of Oral Sciences, Faculty of Dentistry, University of Otago, Dunedin, New Zealand.
A Ferreira-PereiraLaboratório de Bioquímica Microbiana, Departamento de Microbiologia Geral, IMPG/CCS, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil apereira@micro.ufrj.br.ORCID 0000-0002-0474-8388
Universidade Federal do Rio de Janeiro · BRUniversidade de São Paulo · BRInstituto Federal do Rio de Janeiro · BRUniversity of Otago · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive Candida albicans infections are a serious health threat for immunocompromised individuals. Fluconazole is most commonly used to treat these infections, but resistance due to the overexpression of multidrug efflux pumps is of grave concern. This study evaluated the ability of five synthetic organotellurium compounds to reverse the fluconazole resistance of C. albicans clinical isolates. Compounds 1 to 4, at <10 μg/ml, ameliorated the fluconazole resistance of Saccharomyces cerevisiae strains overexpressing the major C. albicans multidrug efflux pumps Cdr1p and Mdr1p, whereas compound 5 only sensitized Mdr1p-overexpressing strains to fluconazole. Compounds 1 to 4 also inhibited efflux of the fluorescent substrate rhodamine 6G and the ATPase activity of Cdr1p, whereas all five of compounds 1 to 5 inhibited Nile red efflux by Mdr1p. Interestingly, all five compounds demonstrated synergy with fluconazole against efflux pump-overexpressing fluconazole-resistant C. albicans clinical isolates, isolate 95-142 overexpressing CDR1 and CDR2, isolate 96-25 overexpressing MDR1 and ERG11, and isolate 12-99 overexpressing CDR1, CDR2, MDR1, and ERG11 Overall, organotellurium compounds 1 and 2 were the most promising fluconazole chemosensitizers of fluconazole-resistant C. albicans isolates. Our data suggest that these novel organotellurium compounds inhibit pump efflux by two very important and distinct families of fungal multidrug efflux pumps: the ATP-binding cassette transporter Cdr1p and the major facilitator superfamily transporter Mdr1p.

Indexed as

Antifungal AgentsCandida albicansDrug Resistance, FungalFluconazoleFungal ProteinsGene Expression Regulation, FungalMicrobial Sensitivity TestsOrganotechnetium CompoundsSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsAntifungal AgentsFluconazoleFungal ProteinsOrganotechnetium CompoundsSaccharomyces cerevisiae Proteinsefflux pumpsmultidrug resistanceorganotelluriumyeasts

Identifiers

PMID27821447
PMCPMC5192104
OpenAlexW2550963350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.